Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Buy dildos and vibrators.
Popular Articles

Boston Scientific Begins Clinical Trial For Next-Generation Nitinol Stent To Treat Iliac Artery Disease
Boston Scientific Corporation (NYSE: BSX) announced the start of patient enrollment in the ORION clinical trial, which is designed to evaluate the Company"s EPIC(TM) Self-Expanding Nitinol Stent System for the treatment of iliac artery disease, a form of peripheral artery disease that impacts a patient"s lower extremities. The first U.S. patient was enrolled on May 14 by Nicolas W. Shammas, M.D., at Trinity Terrace Park Hospital in Bettendorf, Iowa.
buy viagra
Sunwin International Increases Availability Of Two Veterinary Medicines To Combat Swine Flu Virus In China
Sunwin International Neutraceuticals, Inc. (OTCBB: SUWN), a leader in the production and distribution of Chinese herbs, veterinary medicines and one of the world"s leading producers of all natural, zero calorie Stevia in China, announced today that the company has increased the availability of two veterinary medicines, Huangqiduotang vaccine and Jinfang Detoxification Powder to treat swine flu that has recently spread in North America and other parts of the world. These products, currently used for controlling various types of influenza in China, have demonstrated effectiveness in controlling swine flu outbreaks among livestock.
News of the day
Echo-Location In Humans Developed By Spanish Scientists
A team of researchers from the University of Alcalá de Henares (UAH) has shown scientifically that human beings can develop echolocation, the system of acoustic signals used by dolphins and bats to explore their surroundings. Producing certain kinds of tongue clicks helps people to identify objects around them without needing to see them, something which would be especially useful for the blind.
Medical Devices

Arthritis Drug Shows Promise In Clinical Trial

A clinical trial of masitinib, a drug in development for the treatment of rheumatoid arthritis, has shown it to be well tolerated and effective. Researchers writing in BioMed Central"s open access journal Arthritis Research and Therapy have shown that treatment with masitinib significantly reduced the severity of active arthritis. Olivier Hermine worked with researchers from several French hospitals to carry out this trial in 43 patients with arthritis resistant to current treatments. He said, "In choosing which interventions to use for the management of rheumatoid arthritis, it is important to recognise that treatment should aim to keep the disease in remission and not be used intermittently to manage exacerbations. We are encouraged from this study that masitinib not only appears to be effective, but that within the first 3 months of treatment the worst of its side-effects were over, possibly making it suitable for long-term treatment regimens". He adds, "The results of this study also help establish the critical role of mast cells in the pathogenesis of rheumatoid arthritis and demonstrate their viability as a therapeutic target. There is sufficient compelling evidence to warrant further placebo-controlled investigation". Masitinib inhibits the activity of mast cells, a component of the immune system thought to be involved in the pathogenesis of rheumatoid arthritis. The clinical improvement described in the study was supported by laboratory evidence of reduced inflammation. The authors found that adverse effects of the treatment were mainly mild to moderate. Alain Moussy from AB Science, a pharmaceutical company who are developing masitinib for multiple indications in human and animal medicine said, "This is a milestone article for us, being the first publication of masitinib in a human study". Speaking about the drug, Alain Moussy said, "Our preclinical studies have shown that masitinib selectively targets cell receptors known to be involved in various disease processes but does not affect those associated with toxicity, particularly cardiotoxicity". Notes: Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study Jacques Tebib, Xavier Mariette, Pierre Bourgeois, Renç©-Marc Flipo, Philippe Gaudin, Xavier Le Loç«t, Paul Gineste, Laurent Guy, Colin D Mansfield, Alain Moussy, Patrice Dubreuil, Olivier Hermine and Jean Sibilia http://arthritis-research.com/ Graeme Baldwin BioMed Central


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009